Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 15 April, 2011

Lipoxen PLC

Appointment of GE&CR and Initiation of coverage

RNS Number : 0215F
Lipoxen PLC
15 April 2011
 



Lipoxen plc

 

Appointment of commissioned research company and publication of research note

 

Lipoxen (AIM: LPX.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, is pleased to announced the appointment of Growth Equities & Company Research, the commissioned research company.

 

Growth Equities & Company Research has today published a Research note entitled "Lipoxen: Initiate Coverage at 10.5p with a Target Price of 30.7p and Recommendation of Buy" and this can be viewed through the Company website: http://www.lipoxen.com/investor-centre.aspx

 

 

Enquiries:

 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

 

 

 

Walbrook PR Ltd

+44 (0)20 7933 8780

Paul McManus (Media Enquiries)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

Paul Cornelius (Investor Enquiries)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

 

 

 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUAACUPGGGA